(Oslo, 14th of April 2026) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarter in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery, announces that the Board of Medistim ASA has approved the Financial
Statements for 2025. The Financial Statements are without changes from the
preliminary Financial Statements published on the 27th of February 2026. The
annual report for 2025 is now available. The Annual General Meeting will be held
on 6th of May 2025.

About Medistim:
Medistim was established in 1984, and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
Canada, China, Sweden, Japan and Norway, in addition to the about 60
distributors in Europe, Asia, Middle East, Africa, and South America. For more
information, visit the Medistim home page: www.Medistim.com

This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com